|
|
Volumn 27, Issue 15, 2009, Pages 2450-2456
|
|
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (intergroup study 0162) and 9916
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
ESTRAMUSTINE;
MITOXANTRONE;
PREDNISONE;
PROSTATE SPECIFIC ANTIGEN;
ANILIDE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
BICALUTAMIDE;
GOSERELIN;
NITRILE;
TAXOID;
TOLUENESULFONIC ACID DERIVATIVE;
TUMOR MARKER;
ADULT;
AGED;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER MORTALITY;
CANCER SURVIVAL;
CLINICAL TRIAL;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS;
MULTIPLE CYCLE TREATMENT;
OVERALL SURVIVAL;
PREDICTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
BLOOD;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFECT;
MIDDLE AGED;
MORTALITY;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
PROSTATE TUMOR;
RANDOMIZED CONTROLLED TRIAL;
ADULT;
AGED;
AGED, 80 AND OVER;
ANILIDES;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ESTRAMUSTINE;
GOSERELIN;
HUMANS;
MALE;
MIDDLE AGED;
MITOXANTRONE;
NITRILES;
PREDNISONE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
TAXOIDS;
TOSYL COMPOUNDS;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 66349137641
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2008.19.9810 Document Type: Article |
|
Times cited : (172)
|
|
References (8)
|
